Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

U. Banerji · SciRah

Researcher profile · Semantic Scholar

U. Banerji

Share profile

U. Banerji — researcher profile on SciRah

h-index: 52
Works: 332
Citations: 11K

Most-cited papers

Exploiting the folate receptor α in oncology
M. Scaranti, E. Cojocaru, Susana Banerjee, U. Banerji
2020Nature Reviews Clinical Oncology521 citations
Semantic Scholar
Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study.
U. Banerji, C. V. van Herpen, C. Saura, F. Thistlethwaite +13 more
2019The Lancet Oncology473 citations Open access
Semantic Scholar
A Phase I Dose-Escalation Study of AZD3965, an Oral Monocarboxylate Transporter 1 Inhibitor, in Patients with Advanced Cancer
S. Halford, G. Veal, S. Wedge, G. Payne +17 more
2023Clinical Cancer Research255 citations Open access
Semantic Scholar
Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors
T. Yap, Brent O'Carrigan, M. Penney, J. Lim +19 more
2020Journal of Clinical Oncology181 citations Open access
Semantic Scholar
The kinase polypharmacology landscape of clinical PARP inhibitors
A. Antolin, M. Ameratunga, U. Banerji, P. Clarke +2 more
2020Scientific Reports119 citations Open access
Semantic Scholar
Exploiting evolutionary steering to induce collateral drug sensitivity in cancer
A. Acar, D. Nichol, J. Fernández-Mateos, George D. Cresswell +15 more
2020Nature Communications111 citations Open access
Semantic Scholar
Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination With Fulvestrant in Patients With AKT1E17K-Mutant, ER-Positive Metastatic Breast Cancer
L. Smyth, K. Tamura, M. Oliveira, E. Ciruelos +24 more
2020Clinical Cancer Research91 citations Open access
Semantic Scholar
Phase I trial of the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib and AKT inhibitor capivasertib in patients with BRCA1/2 and non-BRCA1/2 mutant cancers
T. Yap, R. Kristeleit, V. Michalarea, S. Pettitt +32 more
2020Cancer Discovery60 citations Open access
Semantic Scholar
Intermittent schedules of the oral RAF-MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study.
Christina Guo, M. Chénard-Poirier, D. Roda, Maria de Miguel +22 more
2020The Lancet Oncology58 citations Open access
Semantic Scholar
First-in-human study of AT13148, a dual ROCK-AKT inhibitor in patients with solid tumors
R. McLeod, Rajiv Kumar, D. Papadatos-Pastos, J. Mateo +16 more
2020Clinical Cancer Research57 citations Open access
Semantic Scholar
Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors
D. Papadatos-Pastos, W. Yuan, Abhijit Pal, M. Crespo +27 more
2022Journal for ImmunoTherapy of Cancer56 citations Open access
Semantic Scholar
Treatment-related adverse events of antibody drug-conjugates in clinical trials
H. N. Tan, M. Morcillo, Juanita Lopez, A. Minchom +5 more
2025Journal of Hematology & Oncology47 citations Open access
Semantic Scholar
A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancer
R. Kristeleit, R. Plummer, Robert Jones, L. Carter +10 more
2023British Journal of Cancer41 citations Open access
Semantic Scholar
Safety and anti-tumour activity of the IgE antibody MOv18 in patients with advanced solid tumours expressing folate receptor-alpha: a phase I trial
J. Spicer, B. Basu, A. Montes, U. Banerji +28 more
2023Nature Communications40 citations Open access
Semantic Scholar
A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced Cancer
Robert Jones, R. Plummer, V. Moreno, L. Carter +12 more
2022Clinical Cancer Research38 citations Open access
Semantic Scholar
Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer
L. Smyth, G. Batist, F. Meric-Bernstam, P. Kabos +23 more
2021npj Breast Cancer30 citations Open access
Semantic Scholar
A phase I dose escalation and expansion study of the next generation oral SERD AZD9833 in women with ER-positive, HER2-negative advanced breast cancer.
E. Hamilton, M. Oliveira, U. Banerji, C. Hernando +16 more
2020Journal of Clinical Oncology29 citations Open access
Semantic Scholar
Inactivation of NF1 promotes resistance to EGFR inhibition in KRAS/NRAS/BRAFV600-wildtype colorectal cancer
A. Georgiou, A. Stewart, D. Cunningham, U. Banerji +1 more
2020Molecular Cancer Research26 citations Open access
Semantic Scholar
Efficacy and Safety of Weekly Paclitaxel Plus Vistusertib vs Paclitaxel Alone in Patients With Platinum-Resistant Ovarian High-Grade Serous Carcinoma: The OCTOPUS Multicenter, Phase 2, Randomized Clinical Trial.
Susana Banerjee, G. Giannone, A. Clamp, D. Ennis +16 more
2023JAMA Oncology25 citations Open access
Semantic Scholar
Abstract PS11-05: Updated data from SERENA-1: A Phase 1 dose escalation and expansion study of the next generation oral SERD AZD9833 as a monotherapy and in combination with palbociclib, in women with ER-positive, HER2-negative advanced breast cancer
R. Baird, M. Oliveira, E. C. Gil, M. Patel +32 more
2021Poster Session Abstracts24 citations
Semantic Scholar
A first-in-human phase I/II trial of SRA737 (a Chk1 Inhibitor) in subjects with advanced cancer.
E. Plummer, R. Kristeleit, E. Cojocaru, N. Haris +15 more
2019Journal of Clinical Oncology24 citations
Semantic Scholar
HER3 expression and MEK activation in non-small-cell lung carcinoma
T. Manickavasagar, W. Yuan, S. Carreira, B. Gurel +12 more
2021Lung Cancer Management20 citations Open access
Semantic Scholar
Abstract CT141: Phase 1 trial of MOv18, a first-in-class IgE antibody therapy for cancer
J. Spicer, B. Basu, A. Montes, U. Banerji +31 more
2020Tumor Biology20 citations
Semantic Scholar
Radiological evaluation of malignant pleural mesothelioma - defining distant metastatic disease
D. Collins, R. Sundar, Anastasia Constantidinou, D. Dolling +8 more
2020BMC Cancer18 citations Open access
Semantic Scholar
A phase I/II first-in-human trial of oral SRA737 (a Chk1 inhibitor) given in combination with low-dose gemcitabine in subjects with advanced cancer.
U. Banerji, E. Plummer, V. Moreno, J. Ang +16 more
2019Journal of Clinical Oncology18 citations
Semantic Scholar
The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers
G. Saturno, F. Lopes, I. Niculescu-Duvaz, D. Niculescu-Duvaz +19 more
2020Annals of Oncology17 citations Open access
Semantic Scholar
Clinical trial designs for evaluating and exploiting cancer evolution.
A. I. Ingles Garces, N. Porta, T. Graham, U. Banerji
2023Cancer Treatment Reviews16 citations Open access
Semantic Scholar
A genome-scale CRISPR screen identifies the ERBB and mTOR signalling networks as key determinants of response to PI3K inhibition in pancreatic cancer
Charlotte K. Milton, A. Self, P. Clarke, U. Banerji +3 more
2020Molecular Cancer Therapeutics16 citations Open access
Semantic Scholar
Abstract CT143: Phase I study of the combination of a RAF-MEK inhibitor CH5126766 and FAK inhibitor defactinib in an intermittent dosing schedule with expansions inKRASmutant cancers
Rajiv Shinde, Angelika Terbuch, M. Little, Reece Caldwell +20 more
2020Tumor Biology16 citations
Semantic Scholar
Individualized Prediction of Drug Response and Rational Combination Therapy in NSCLC Using Artificial Intelligence–Enabled Studies of Acute Phosphoproteomic Changes
E. Coker, A. Stewart, Bugra Ozer, A. Minchom +9 more
2022Molecular Cancer Therapeutics15 citations Open access
Semantic Scholar
725MO Phase I study of the combination of the dual RAF/MEK inhibitor VS-6766 and the FAK inhibitor defactinib: Results of efficacy in low grade serous ovarian cancer
Sri Banerjee, R. Grochot, R. Shinde, J. Lima +14 more
2021Annals of Oncology15 citations Open access
Semantic Scholar
Radiological Patterns of Drug-induced Interstitial Lung Disease (DILD) in Early-phase Oncology Clinical Trials
Angelika Terbuch, C. Tiu, I. M. Candilejo, M. Scaranti +11 more
2020Clinical Cancer Research13 citations Open access
Semantic Scholar
Exploiting evolutionary herding to control drug resistance in cancer
A. Acar, D. Nichol, J. Fernández-Mateos, George D. Cresswell +12 more
2019bioRxiv12 citations Open access
Semantic Scholar
SARS-CoV-2 vaccination and phase 1 cancer clinical trials
T. Yap, L. Siu, E. Calvo, M. Lolkema +6 more
2021The Lancet Oncology11 citations Open access
Semantic Scholar
Molecular and immunological features of a prolonged exceptional responder with malignant pleural mesothelioma treated initially and rechallenged with pembrolizumab
A. Minchom, W. Yuan, M. Crespo, B. Gurel +18 more
2020Journal for ImmunoTherapy of Cancer11 citations Open access
Semantic Scholar
Phase I trial of acoustic cluster therapy (ACT) with chemotherapy in patients with liver metastases of gastrointestinal origin (ACTIVATE study).
U. Banerji, C. Tiu, A. Curcean, Sumita Gurung +11 more
20219 citations
Semantic Scholar
A phospho-proteomic study of cetuximab resistance in KRAS/NRAS/BRAFV600 wild-type colorectal cancer
A. Georgiou, A. Stewart, G. Vlachogiannis, L. Pickard +4 more
2021Cellular Oncology9 citations Open access
Semantic Scholar
Abstract CT185: First in human dose-escalation trial with the c-MET targeting antibody-drug conjugate BYON3521
N. Kotecki, C. V. van Herpen, C. Curigliano, M. Hendriks +8 more
2023Cancer Research8 citations
Semantic Scholar
Abstract CT503: A phase I/Ib study of the safety and preliminary efficacy of NZV930 alone and in combination with spartalizumab and/or taminadenant in patients (pts) with advanced malignancies
S. Fu, U. Banerji, Philippe Bédard, A. Ferrandiz +12 more
2022Cancer Research8 citations
Semantic Scholar
A Wolf in Sheep's Clothing: Systemic Immune Activation Post Immunotherapy
C. Tiu, Rajiv Shinde, Abhijit Pal, A. Biondo +11 more
2021Journal of Immunotherapy and Precision Oncology8 citations Open access
Semantic Scholar
Abstract CT019: A phase I trial of the combination of the dual RAF-MEK inhibitor VS-6766 and the FAK inhibitor defactinib: Evaluation of efficacy in KRAS mutated NSCLC
M. Krebs, Rajiv Shinde, R. Rahman, R. Grochot +12 more
2021Clinical Trials7 citations
Semantic Scholar
Phase I trial of the RAF/MEK clamp VS-6766 in combination with everolimus using an intermittent schedule with expansion in NSCLC across multiple KRAS variants.
A. Minchom, Vicky Sánchez-Pérez, Cienne Morton, T. Manickavasagar +14 more
2022Journal of Clinical Oncology6 citations
Semantic Scholar
A Phase I Trial of CT900, a Novel α-Folate Receptor–Mediated Thymidylate Synthase Inhibitor, in Patients with Solid Tumors with Expansion Cohorts in Patients with High-Grade Serous Ovarian Cancer
Susana Banerjee, V. Michalarea, J. Ang, A. I. Ingles Garces +25 more
2022Clinical Cancer Research6 citations Open access
Semantic Scholar
Searching for treatments for non-G12C-KRAS mutant cancers
Christina Guo, U. Banerji
2021British Journal of Cancer6 citations Open access
Semantic Scholar
Abstract CT120: Results of the glioblastoma multiforme (GBM) cohort of phase 1 trial Ice-CAP (NCT03673787): Preliminary evidence of antitumour activity of Ipatasertib (Ipa) and Atezolizumab (A) in patients (pts) with PTEN loss
C. Tiu, A. Biondo, L. Welsh, T. Jones +16 more
2021Clinical Trials6 citations
Semantic Scholar
Unbiased differential proteomic profiling between cancer-associated fibroblasts and cancer cell lines.
Rachel Lau, Lu Yu, Theo Roumeliotis, A. Stewart +6 more
2023Journal of Proteomics5 citations Open access
Semantic Scholar
A single‐centre study evaluating a geriatric screening tool in oncology phase I trial patients
M. Van Zyl, Anne Barell, Bridget Cooley, J. Hanwell +7 more
2024Cancer Reports4 citations Open access
Semantic Scholar
Abstract CT093: Preliminary evidence of antitumor activity of Ipatasertib (Ipat) and Atezolizumab (A) in glioblastoma (GBM) patients (pts) with PTEN loss in the Phase 1 Ice-CAP trial (NCT03673787)
C. Tiu, Wing Yau, L. Welsh, T. Jones +16 more
2023Cancer Research4 citations
Semantic Scholar
Metabolomic changes of the multi (-AGC-) kinase inhibitor AT13148 in cells, mice and patients are associated with NOS regulation
A. Pál, Yasmin Asad, R. Ruddle, A. Henley +8 more
2020Metabolomics4 citations Open access
Semantic Scholar
A risk-based approach to experimental early phase clinical trials during the COVID-19 pandemic
C. Tiu, Rajiv Shinde, C. Yap, Bindumalini Rao Baikady +4 more
2020The Lancet Oncology4 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

J. de Bono×21
Invite
J. de Bono — researcher profile on SciRah
Juanita Lopez×17
Invite
Juanita Lopez — researcher profile on SciRah
A. Minchom×17
Invite
A. Minchom — researcher profile on SciRah
N. Tunariu×14
Invite
N. Tunariu — researcher profile on SciRah

×11

Invite

R. Riisnaes — researcher profile on SciRah

Invite

A. Turner — researcher profile on SciRah

Invite

M. Parmar — researcher profile on SciRah

Invite

S. Carreira — researcher profile on SciRah

R. Kristeleit×8

Invite

R. Kristeleit — researcher profile on SciRah

Invite

B. Gurel — researcher profile on SciRah

Invite

A. Stewart — researcher profile on SciRah

Invite

R. Ruddle — researcher profile on SciRah